Cohort study compares homocysteine and uric acid levels in Parkinson's disease-related and post-stroke cognitive impairment.
This observational cohort study evaluated metabolic profiles in patients diagnosed with cognitive impairment. The population comprised 60 patients with Parkinson's disease-related cognitive impairment and 60 patients with post-stroke cognitive impairment admitted to the Department of Neurology at Yangjiang Hospital of Traditional Chinese Medicine. Follow-up duration was not reported in the study design.
Primary outcomes included homocysteine (Hcy) and uric acid (UA) levels. The PD-CI group exhibited significantly higher Hcy levels with an adjusted mean difference of 2.55 μmol/L (95% CI: 0.23–4.87, p = 0.032). Conversely, UA levels were significantly lower in PD-CI with an adjusted mean difference of −34.66 μmol/L (95% CI: −63.87 to −5.46, p = 0.020). Hcy negatively correlated with MMSE scores in the overall sample (r = −0.309, p = 0.001). The association of Hcy with MMSE was numerically stronger in the PD-CI group (r = −0.456), though the p-value was not reported. UA levels were independently associated with disease type.
Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The study is limited as an exploratory cross-sectional analysis requiring validation in prospective studies. Findings suggest potential differences in metabolic profiles and may offer new insights for clinical differential diagnosis, though causality cannot be established. Funding or conflicts of interest were not reported.